---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000017"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:46:23.472579+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance

## Summary
- FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.
- FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.
- Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.
- On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.
- Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO.

## SEC filing metadata
- accession: 0000078003-25-000017
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/0000078003-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/pfe-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000017
- JSON: https://secwatch.observer/filing/0000078003-25-000017.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.